CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 31 enrolled
Drug / intervention
Electronic Cigarette Aerosoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03479203
NCT03479203Early Ph 1Completed
CompareCT.gov

Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity

University of Pennsylvania·interventional·Posted Mar 27, 2018·Updated May 8, 2024

In Brief

A Early Phase 1 clinical trial evaluating Electronic Cigarette Aerosol for Endothelial Dysfunction and Biochemical Markers. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study comprises a portion of a larger study designed to compare results of vascular function in non-smokers to vascular function in healthy smokers chronically exposed to nicotinized electronic cigarette aerosol versus conventional cigarettes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndothelial Dysfunction, Biochemical Markers
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedMar 27, 2018
Enrollment StartMay 22, 2018
Primary CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.3 years ago

Interventions

Electronic Cigarette Aerosoldrug

16 two-second-long puffs from a non-nicotinized electronic cigarette.